This is a working overview of retatrutide, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2025-10-21. Anything still debated is marked as such rather than presented as settled.
Pharmacologically, retatrutide acts as a triple agonist at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor. Activation of the first two receptors is associated with improved insulin secretion and reduced appetite. The glucagon receptor component is thought to increase energy expenditure, a mechanism that distinguishes this molecule from dual-agonist compounds. Researchers continue to investigate how the three activities interact and whether the combined profile offers advantages that justify additional clinical testing.
Several questions about the compound remain unresolved. The durability of weight reduction after treatment stops, the frequency of gastrointestinal side effects, and the long-term cardiovascular profile are topics of ongoing study. Regulatory submissions and phase 3 trial outcomes have not been fully reported in the public literature. Because most available data come from controlled trials rather than general-population use, conclusions about effectiveness outside study settings are provisional. The distinction between established findings and open questions matters when interpreting early coverage of the drug.
Development has progressed from single- and multiple-ascending-dose studies in healthy volunteers into larger randomized trials in adults with obesity, type 2 diabetes, and fatty liver disease. Early reports describe dose-dependent reductions in body weight and improvements in glycemic markers over treatment periods of several months. Whether the glucagon arm adds tolerability cost without added benefit is still debated. Long-term cardiovascular outcomes, effects after treatment stops, and performance in older or comorbid populations are open questions rather than settled findings. Approval status may change, so the current investigational label should be confirmed against regulatory sources.
Retatrutide is an investigational synthetic peptide developed under the code LY3437943, with a backbone derived from glucose-dependent insulinotropic polypeptide. Several non-proteinogenic residues, including alpha-aminoisobutyric acid, appear in that backbone, and a fatty diacid side chain attached through a linker extends circulation time. The molecule carries roughly thirty-nine amino acid units and a total mass near 4.7 kilodaltons. Administration is by subcutaneous injection once weekly. Published work uses both the name retatrutide and the code LY3437943.
Pharmacologically the compound activates three receptors: GLP-1, GIP, and glucagon. GLP-1 and GIP signaling contribute to glucose-dependent insulin release, delayed gastric emptying, and reduced appetite, while glucagon receptor activation is associated with increased energy expenditure and hepatic fat oxidation. The single-molecule design is intended to keep these activities in one peptide rather than combining separate agents. Relative activity at each receptor differs, and the balance between them is a central question in interpretation. The glucagon component is partly offset by incretin-mediated insulin secretion, an interaction that remains incompletely characterized.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Contains non-natural residues |
| Receptor targets | GLP-1, GIP, glucagon | Triple agonist profile |
| Route of administration | Subcutaneous injection | In clinical trial settings |
| Development status | Investigational | Not approved in major markets |
| Approximate molecular mass | About 4.7 kDa | Peptide-scale molecule |
The peptide backbone is chemically modified to resist rapid enzymatic breakdown in the body. A fatty acid side chain promotes binding to serum albumin, which slows renal clearance and supports an extended circulation time. These modifications allow less frequent administration than would be possible with an unmodified peptide. The precise contribution of glucagon receptor activation to the overall metabolic effect remains an area of active investigation, because glucagon raises glucose while also increasing energy expenditure.
Development has progressed through early- and mid-stage human studies in adults with obesity and with type 2 diabetes. Published phase 2 data reported reductions in body weight and improvements in glycemic markers over the treatment period. No regulatory agency has approved the compound for any indication, and it remains available only within controlled research settings. Whether benefits observed in trials translate into durable outcomes after treatment stops is not yet established.
Human evidence remains limited to controlled studies. A phase 2 trial in adults with obesity reported large, dose-dependent reductions in body weight over 48 weeks, with gastrointestinal events as the most frequently recorded adverse effect. Phase 3 programs designated TRIUMPH, for obesity, and TRANSCEND, for type 2 diabetes, are intended to confirm efficacy and to characterize safety in larger populations. Related studies are examining conditions such as knee osteoarthritis in people with obesity and metabolic liver disease. Open questions include long-term tolerability, effects on lean mass, and what happens after treatment is stopped.
Retatrutide is an investigational synthetic peptide that acts on three receptor targets at once: glucose-dependent insulinotropic polypeptide, glucagon-like peptide-1, and glucagon. It is developed by Eli Lilly and appears in the literature and in trial registries under the code LY3437943. The molecule belongs to a class of engineered peptides designed to resist rapid breakdown and permit infrequent subcutaneous administration. No regulatory agency has approved it for clinical use, and all available human data come from controlled trials rather than from routine practice.
The legislative branch of government is a unicameral legislative assembly, whose tenure is five years. The legislative assembly may make laws for any of the matters in the State List of the Constitution of India except "public order" and "police", which will remain the preserve of the central Government of India. The Lieutenant Governor also has the power to promulgate ordinances which have the same force as the acts of the legislative assembly. Elections for the Jammu and Kashmir Legislative Assembly were held in September and October 2024.
== Felinine variables == Felinine excretion is regulated by levels of testosterone, and so its concentration is dependent on the sex and age of the cat. For instance, cats with high levels of testosterone produce higher levels of 3-MBG. Consequently, non neutered males have significantly higher concentrations of felinine in their urine than females and neutered males. Furthermore, cauxin is a carboxylesterase enzyme which hydrolyzes 3-methylbutanol-cysteinylglycine (MBCG) into felinine. Thus, felinine is dependent upon cauxin, and cauxin is excreted most in male cats above the age of three months. Therefore, older cats, compared to young kittens, have higher concentrations of felinine. Also, long hair cats have less cysteine to go around as the amino acid is also used for protein structures found in hair. Thus, long-haired cats make less felinine than short-haired cats. The urea in cat urine has been found to react with the felinine in the urine. After synthetic felinine was incubated in urea, none of it was recovered, suggesting a degradation or modification of felinine. However, evidence suggests that the interaction does not stem from a nucleophilic reaction. It has been found that dietary supplementation with amino acids other than cysteine impact felinine excretion. This is most likely caused by the presence of arginine, which is believed to inhibit synthesis of MBG, which decreases felinine excretion.
Cocaine is sometimes used in otorhinolaryngology as a topical anesthetic and vasoconstrictor to help control pain and bleeding during surgery of the nose, mouth, throat, or lacrimal duct. It is also used for topical airway anaesthesia for procedures such as awake fibreoptic bronchoscopy or intubation. Although some absorption and systemic effects may occur, the use of cocaine as a topical anesthetic and vasoconstrictor is generally safe, rarely causing cardiovascular toxicity, glaucoma, and pupil dilation. Occasionally, cocaine is mixed with adrenaline and sodium bicarbonate and used topically for surgery, a formulation called Moffett's solution. It is occasionally used in surgeries involving the pharynx or nasopharynx to reduce pain, bleeding, and vocal cord spasm. Nasal solution cocaine hydrochloride (Goprelto), an ester used for intranasal application, was approved for medical use in the United States in December 2017, and is indicated for the introduction of topical anesthesia of the mucous membranes for diagnostic procedures and surgeries on or through the nasal cavities of adults. Cocaine hydrochloride (Numbrino) was approved for medical use in the United States in January 2020. Headache and epistaxis are the most frequently reported adverse reactions with Goprelto, while hypertension and tachycardia-including sinus tachycardia-are most common with Numbrino.
=== Apodization in mass spectrometry === During oscillation within an Orbitrap, a transient signal may not be stable until the ions settle into their oscillations. Toward the end, subtle ion collisions add up to cause noticeable dephasing. This presents a problem for the Fourier transform, as it averages the oscillatory signal across the length of the time-domain measurement. Software allows "apodization", the removal of the front and back section of the transient signal from consideration in the FT calculation. Thus, apodization improves the resolution of the resulting mass spectrum. Another way to improve the quality of the transient is to wait to collect data until ions have settled into stable oscillatory motion within the trap.
== Operations == UPS's primary business is the time-definite delivery of packages and documents worldwide. In recent years, UPS has extended its service portfolio to include less-than-truckload (LTL) transportation and supply chain services, primarily in the U.S. UPS reports its operations in three segments:
Sources: en.wikipedia.org
CSL's vaccine for swine flu, the world's first, was approved in September 2009 for use by people over age 10. The federal government ordered 21 million doses of vaccine for Australians. CSL also provided vaccines for customers in Singapore and the US. On 28 September 2010, the Australian Therapeutic Goods Administration (TGA) conducted an analysis of febrile convulsions following immunisation in children following monovalent pandemic H1N1 vaccine (Panvax/Panvax Junior, CSL). A paper published in the Medical Journal of Australia provides a possible reason for CSL's 2010 flu vaccine causing febrile convulsions in children. The authors hypothesise that suboptimal use of the detergent called deoxycholate – used in the manufacturing process by CSL (one of the few vaccine manufacturers that use it) – to split the flu virus from its membrane may be at fault.
This movement resulted in an intense cultural exchange and resulted in the formation of mestizos (in Spanish) or caboclos (in Portuguese), a social category formed by people with mixture of European and native ancestry, who were an important part of the economy and culture of the region. According to Peter Gow, the ayahuasca shamanism (the use of ayahuasca by a trained shaman to diagnose and cure illnesses) was developed by these mestizos in the processes of colonial transformation. The Amazon rubber cycles (1879–1912 and 1942–1945) sped up these transformations, due to slavery, genocide and brutality against indigenous populations and large migratory movements, specially from the Brazilian Northeast Region as a workforce for the rubber plantations. The mestizo practices became deeply intertwined with the culture of rubber workers, called caucheros (in Spanish) or seringueiros (in Portuguese). Ayahuasca use with therapeutic goals is the main result of this Trans-cultural diffusion, with some practitioners pointing the caucheros as the main responsible for using ayahuasca to cure all sort of ailments of the body, mind and soul, with even some regions using the term Yerba de Cauchero ("rubber-worker herb"). As a result, the ayahuasca shamans in urban areas and mestizo settlements, specially in the regions of Iquitos and Pucallpa (in Peru), became the vegetalistas, folk healers who are said to gain all their knowledge from the plants and the spirits bound to it.
Furthermore, in the 1951 film Προ παντός ψυχραιμία (Pro pantós psykhaimía, Above all, stay calm) starring Mimis Fotopoulos and Dinos Iliopoulos, Iliopoulos makes a direct reference to frappé coffee, which the two protagonists prepared with a shaker at Pavlidis Patisserie on Amerikis Square in Athens: "If we make even the slightest mistake, they’ll turn us into a frappé!". Vakondios' improvised experiment is thought to have established the frappé which quickly grew in popularity in Greece. Nestlé capitalized on the drink with intense marketing campaigns in the 1980s that broadened the drink's popularity and left the brand name Nescafé inextricably linked with the frappé. Today, the drink is usually simply called a 'frappé' in Greece, but in the past, it was often called a 'Nescafé frappé'.
== Products == Novo produces the drug semaglutide, used to treat diabetes under the brand names Ozempic and Rybelsus and obesity under the brand name Wegovy. Novo is also involved with hemostasis management, growth hormone therapy, and hormone replacement therapy. The company makes several drugs under various brand names, including Levemir, Tresiba, NovoLog, Novolin R, NovoSeven, NovoEight, and Victoza.
Sources: en.wikipedia.org
=== Metals === The biological half-life of caesium in humans is between one and four months. This can be shortened by feeding the person prussian blue. The prussian blue in the digestive system acts as a solid ion exchanger which absorbs the caesium while releasing potassium ions. For some substances, it is important to think of the human or animal body as being made up of several parts, each with its own affinity for the substance, and each part with a different biological half-life (physiologically-based pharmacokinetic modelling). Attempts to remove a substance from the whole organism may have the effect of increasing the burden present in one part of the organism. For instance, if a person who is contaminated with lead is given EDTA in a chelation therapy, then while the rate at which lead is lost from the body will be increased, the lead within the body tends to relocate into the brain where it can do the most harm.
=== Experiments with cathode rays === Earlier, physicists debated whether cathode rays were immaterial like light ("some process in the aether") or were "in fact wholly material, and ... mark the paths of particles of matter charged with negative electricity", quoting Thomson. The aetherial hypothesis was vague, but the particle hypothesis was definite enough for Thomson to test.
== Refrigeration cycle == ULT freezers that employ the cascade refrigeration (CR) system use up to 20 times the energy footprint of household fridges, and used to refrigerate with greenhouse gas fluids (typically hydrofluorocarbon R-508B). Modern ULT freezers employ HC (i.e., hydrocarbon) gas mixtures: typically, ethane and propane. This technology was developed in the mid-1990s, and improved efficiency by up to 30% over the conventional CFC or HFC gassed freezers. Alternatively ULT freezers may use the Stirling cycle in reverse (A Stirling cooler) for refrigeration.
February 23, 2011 Venezuela Economists expressed concern with regards to Venezuela's economy improving due to instability in the private sector pressured by the socialist government, as José Guerra, former manager at the Central Bank of Venezuela, stated that private investment, accounting for half of Venezuela's GDP, dropped 2.2% in 2010.
Level one, flat tissue like skin was the simplest to recreate; Level two was tubular structures such as blood vessels; Level three was hollow non-tubular structures; Level four was solid organs, which were by far the most complex to recreate due to the vascularity. In 2012, within 60 days it was possible, inside the lab, to grow tissue the size of half a postage stamp to the size of a football field. Most cell types could be grown and expanded outside of the body, with the exception of the liver, nerve and pancreas, as these tissue types need stem cell populations.
Sources: en.wikipedia.org
It is designed as a triple agonist acting on the GLP-1, GIP, and glucagon receptors. This combination is intended to influence appetite, insulin secretion, and energy expenditure. Single-receptor and dual-receptor compounds act on a narrower set of targets.
No. It remains investigational, and phase 3 results have not been fully published or reviewed by regulators. Official approval status should be confirmed through regulatory agencies rather than secondary sources.
The added glucagon receptor activity is the main difference in its mechanism. Whether that addition produces meaningful benefits in clinical outcomes is still being studied. Comparisons between compounds rest largely on indirect rather than head-to-head trial data.
As of the mid-2020s retatrutide remains investigational and is not an approved medicine in the United States or the European Union. It has been supplied mainly to participants in clinical trials. Labels and availability can change, so regulatory listings should be checked directly.